SCA
EIGR

SAC Capital Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

SAC Capital Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-77
Closed -$415K – 1114
2014
Q1 		$415K Buy
+77
New +$364K ﹤0.01% 1269

Other funds holding EIGR

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

SAC Capital Advisors's EIGR Position: Q2 2014 in Review

SAC Capital Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2014, closing a stake of 77 shares — an estimated $415K sold.

SAC Capital Advisors first reported a position in EIGR in Q1 2014 and held it in 1 quarter. The position peaked at $415K in Q1 2014. 40 funds tracked by Wall St. Rank hold EIGR as of Q2 2014.

  • SAC Capital Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 77 Eiger BioPharmaceuticals, Inc. shares in Q2 2014, an estimated $415K.
  • SAC Capital Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $415K in Q1 2014.
  • 40 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.